ARCT
Price
$17.85
Change
+$1.09 (+6.50%)
Updated
Sep 5 closing price
Capitalization
484.71M
60 days until earnings call
DMAC
Price
$6.14
Change
+$0.77 (+14.34%)
Updated
Sep 5 closing price
Capitalization
317.37M
60 days until earnings call
Interact to see
Advertisement

ARCT vs DMAC

Header iconARCT vs DMAC Comparison
Open Charts ARCT vs DMACBanner chart's image
Arcturus Therapeutics Holdings
Price$17.85
Change+$1.09 (+6.50%)
Volume$511.46K
Capitalization484.71M
DiaMedica Therapeutics
Price$6.14
Change+$0.77 (+14.34%)
Volume$754.56K
Capitalization317.37M
ARCT vs DMAC Comparison Chart in %
Loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARCT vs. DMAC commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Hold and DMAC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (ARCT: $17.85 vs. DMAC: $6.14)
Brand notoriety: ARCT and DMAC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 93% vs. DMAC: 205%
Market capitalization -- ARCT: $484.71M vs. DMAC: $317.37M
ARCT [@Biotechnology] is valued at $484.71M. DMAC’s [@Biotechnology] market capitalization is $317.37M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whileDMAC’s FA Score has 0 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • DMAC’s FA Score: 0 green, 5 red.
According to our system of comparison, ARCT is a better buy in the long-term than DMAC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 6 TA indicator(s) are bullish while DMAC’s TA Score has 5 bullish TA indicator(s).

  • ARCT’s TA Score: 6 bullish, 4 bearish.
  • DMAC’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both ARCT and DMAC are a good buy in the short-term.

Price Growth

ARCT (@Biotechnology) experienced а +4.94% price change this week, while DMAC (@Biotechnology) price change was +7.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.48%, and the average quarterly price growth was +31.71%.

Reported Earning Dates

ARCT is expected to report earnings on Nov 05, 2025.

DMAC is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARCT($485M) has a higher market cap than DMAC($317M). DMAC YTD gains are higher at: 13.076 vs. ARCT (5.186). DMAC has higher annual earnings (EBITDA): -31.42M vs. ARCT (-54.54M). ARCT has more cash in the bank: 196M vs. DMAC (30M). DMAC has less debt than ARCT: DMAC (292K) vs ARCT (27M). ARCT has higher revenues than DMAC: ARCT (110M) vs DMAC (0).
ARCTDMACARCT / DMAC
Capitalization485M317M153%
EBITDA-54.54M-31.42M174%
Gain YTD5.18613.07640%
P/E RatioN/AN/A-
Revenue110M0-
Total Cash196M30M653%
Total Debt27M292K9,247%
FUNDAMENTALS RATINGS
ARCT vs DMAC: Fundamental Ratings
ARCT
DMAC
OUTLOOK RATING
1..100
8179
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
68
Overvalued
PROFIT vs RISK RATING
1..100
10095
SMR RATING
1..100
9698
PRICE GROWTH RATING
1..100
4042
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARCT's Valuation (43) in the Pharmaceuticals Major industry is in the same range as DMAC (68) in the Biotechnology industry. This means that ARCT’s stock grew similarly to DMAC’s over the last 12 months.

DMAC's Profit vs Risk Rating (95) in the Biotechnology industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that DMAC’s stock grew similarly to ARCT’s over the last 12 months.

ARCT's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as DMAC (98) in the Biotechnology industry. This means that ARCT’s stock grew similarly to DMAC’s over the last 12 months.

ARCT's Price Growth Rating (40) in the Pharmaceuticals Major industry is in the same range as DMAC (42) in the Biotechnology industry. This means that ARCT’s stock grew similarly to DMAC’s over the last 12 months.

ARCT's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as DMAC (100) in the Biotechnology industry. This means that ARCT’s stock grew similarly to DMAC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTDMAC
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
86%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
84%
Momentum
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
85%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 15 days ago
81%
Bullish Trend 1 day ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 3 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 1 day ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
OJOC335.000.50
+0.15%
Ojai Oil Co.
PPCCY58.250.02
+0.03%
PICC Property and Casualty Co., Ltd.
HKSHF0.71N/A
N/A
Hong Kong & Shanghai Hotels
NXPRF149.16N/A
N/A
Nexans Paris ACT
CCUR2500.00N/A
N/A
CCUR Holdings, Inc.

DMAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, DMAC has been loosely correlated with WHWK. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if DMAC jumps, then WHWK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DMAC
1D Price
Change %
DMAC100%
+14.34%
WHWK - DMAC
47%
Loosely correlated
+0.55%
ARCT - DMAC
38%
Loosely correlated
+6.50%
HUMA - DMAC
35%
Loosely correlated
-2.05%
LQDA - DMAC
32%
Poorly correlated
+0.03%
EDIT - DMAC
31%
Poorly correlated
+9.52%
More